24-Month Data and Live Case Presented for Elixir Medical’s DynamX Bioadaptor

January 27, 2021—Elixir Medical announced the 24-month clinical results for the DynamX coronary bioadaptor system, a drug-eluting coronary artery implant that adapts to vessel physiology. Antonio Colombo, MD, coprincipal investigator of the study presented the data at the 30th annual Live Interventions in Vascular Endotherapy in Singapore (Singapore LIVE).

The company advised that the findings presented by Dr. Colombo demonstrated the device’s safety profile through 24 months with no target vessel revascularization (TVR), no myocardial infarction (MI), and no device thrombosis.

“Coronary arteries naturally have the ability to expand with disease progression in order to maintain blood flow to the heart,” commented Dr. Colombo in Elixir Medical’s announcement. “Drug-eluting stents cage the coronary arteries and hinder this physiologic response. DynamX is the first metallic coronary artery implant to demonstrate positive adaptive remodeling of the vessel. At 24 months, the bioadaptor continued to show no thrombosis, no MI, and no TVR, which demonstrates a strong safety profile and excellent performance.”

Dr. Colombo is Professor of Cardiology at Humanitas Medical School, Senior Consultant in Interventional Cardiology at Humanitas Research Hospital, Rossano, Milan, and Director of the Cardiac Catheterization Laboratory in Columbus Hospital, Milan, Italy.

Professor Lim Soo Teik, MD, performed a live case on a patient with triple vessel disease during Singapore LIVE. Prof. Lim, who is Deputy Medical Director and Senior Consultant, Department of Cardiology, and Director of the Cardiac Catheterization Laboratory, National Heart Center Singapore, stated in the press release, “DynamX bioadaptor has demonstrated excellent clinical results, and performed well in the procedure presented at the Singapore LIVE conference. We are hopeful that allowing the artery to expand, preserving blood flow, and restoring artery motion may result in better outcomes for our patients.”

According to Elixir Medical, the DynamX bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating and a radial strength similar to drug-eluting stents. The polymer coating dissolves within 6 months, uncaging the bioadaptor and freeing the artery to move with the natural expansion and contraction of the artery, unlike a DES. This has been shown to maintain the ability for positive adaptive remodeling; restore vessel function; and allow for the vessel’s return toward baseline angulation. The DynamX coronary bioadaptor system has received European CE Mark approval. It is not available for sale in the United States.